Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

32 trials with published results (37%)

Research Maturity

60 completed trials (70% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.5%

3 terminated out of 86 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

69%

59 trials in Phase 3/4

Results Transparency

53%

32 of 60 completed with results

Key Signals

32 with results95% success

Data Visualizations

Phase Distribution

76Total
Not Applicable (1)
P 1 (3)
P 2 (13)
P 3 (44)
P 4 (15)

Trial Status

Completed60
Unknown12
Withdrawn3
Terminated3
Enrolling By Invitation3
Recruiting3

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 60 completed trials

Clinical Trials (86)

Showing 20 of 20 trials
NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT06987942Phase 4CompletedPrimary

Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)

NCT06484686Phase 4Enrolling By InvitationPrimary

An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine

NCT05095701Phase 4Enrolling By InvitationPrimary

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

NCT06314724Phase 3CompletedPrimary

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

NCT06482216Not Yet RecruitingPrimary

Correlation of Protection Against Varicella in an Exploratory Study

NCT06068608Phase 1UnknownPrimary

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

NCT05015686Phase 3Enrolling By InvitationPrimary

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

NCT04471493Recruiting

Pediatric and Ambulatory Research in Infectious Diseases

NCT05422508Phase 2RecruitingPrimary

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

NCT05158777Phase 3CompletedPrimary

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

NCT05952505Phase 4Unknown

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

NCT05839301Phase 3UnknownPrimary

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

NCT05669625Phase 3Active Not RecruitingPrimary

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

NCT05470855Phase 4UnknownPrimary

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

NCT05460429Phase 4UnknownPrimary

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

NCT05526820Phase 4CompletedPrimary

A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine

NCT01190228Phase 3Completed

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV

NCT05150392Phase 3CompletedPrimary

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

NCT00432523Phase 3Completed

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Scroll to load more

Research Network

Activity Timeline